That has been put down to payer resistance as they are so much more expensive than current, generic migraine drugs. Market research firm GlobalData says first-to-market Aimovig – which was ...

The drug provides an alternative to CGRP antagonists delivered by injection or infusion, like Novartis’ Aimovig (erenumab ... are also backed for use in migraine prevention.

[92] Onabotulinum toxin-A is approved for headache prophylaxis in adults with chronic migraine and has approximately the same rate of improvement. Side effects of PAM drugs should be reviewed ...

Triptans is a medication that can help relieve migraine symptoms. Research has found it effective, but it’s not for everyone. Migraine is a neurological condition affecting millions of people ...

may be the anatomical target of some of the current and emerging therapies to relieve migraine symptoms, and why this should prove to be a fruitful area for drug development for the treatment of ...

Amitriptyline has long been used for migraine prevention. Discover how this antidepressant works, its side effects, and why it's still being prescribed.

Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ...

NEW YORK (Reuters) - Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the ...

Traditional treatments for migraine include over-the-counter pain relievers, prescription medications, and preventive therapies. However, many people are turning to alternative remedies, including ...

Pfizer agreed to pay nearly $60 million to resolve allegations that its Biohaven Pharmaceuticals unit paid kickbacks to entice physicians to prescribe a migraine treatment. The alleged violations ...

Among PPI users, 25% reported migraines or severe headaches, compared to 19% of non-users. This finding highlights PPIs as the acid-reducing drug class most strongly associated with headache risk, ...